Replies to post #938 on Chembio Diagnostics Inc (CEMI)

[BottomBounce]

$CEMI 12-month price forecasts for Chembio Diagnostics Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median estimate represents a +225.20% increase from the last price of 2.46.

[BottomBounce]

$CEMI Chembio Diagnostics Got a FDA Emergency Use Nod For Its COVID-19 Antibody Test

The FDA has granted emergency use authorization to Chembio Diagnostics Inc's (NASDAQ: CEMI) COVID-19 antibody test.
The nod comes for LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies in whole human blood, plasma, or serum for indication of recent or prior infection.
Recently, the Company received a $28 million order to supply DPP SARS-CoV-2 Antigen tests for delivery during 2021 in Brazil.

[BottomBounce]

CEMI About the DPP Rapid Test Platform
Chembio’s proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chembio’s portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, ANVISA, and other global organizations, where they aid in the detection and diagnosis of several other critical diseases and conditions.

All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending. https://chembio.com/investors/press-releases/

[BottomBounce]

$cemi 12-month price forecasts for Chembio Diagnostics Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median estimate represents a +223.89% increase from the last price of 2.47.